Glenmark Pharmaceuticals · NSE: GLENMARK · BSE: 532296
Q1 FY21 results · Apr–Jun 2020
Glenmark Pharmaceuticals reported revenue from operations of ₹2,344.79 crore (up 0.9% from Q1 FY20) and net profit of ₹254.04 crore (up 132.5% from Q1 FY20) for Q1 FY21 (Apr–Jun 2020), on a consolidated basis.
| Item | Q1 FY21 | Q1 FY20 | YoY | Q4 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,344.79 | 2,322.88 | +0.9% | 2,767.49 | −15.3% |
| Other income | 58.51 | 1.67 | 35x | 44.15 | +32.5% |
| Total income | 2,403.30 | 2,324.55 | +3.4% | 2,811.63 | −14.5% |
| Profit before tax | 357.61 | 159.84 | +123.7% | 317.96 | +12.5% |
| Net profit for the period | 254.04 | 109.28 | +132.5% | 220.31 | +15.3% |
| EPS, basic (₹) | 9.00 | 3.87 | +132.6% | 7.81 | +15.2% |
| Net margin (%) | 10.8 | 4.7 | 8.0 |
| Item | Q1 FY21 | Q1 FY20 | YoY | Q4 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,682.92 | 1,498.79 | +12.3% | 1,607.73 | +4.7% |
| Other income | 134.85 | 68.54 | +96.7% | 251.29 | −46.3% |
| Total income | 1,817.77 | 1,567.33 | +16.0% | 1,859.02 | −2.2% |
| Profit before tax | 575.84 | 276.94 | +107.9% | 372.55 | +54.6% |
| Net profit for the period | 462.48 | 227.84 | +103.0% | 349.19 | +32.4% |
| EPS, basic (₹) | 16.39 | 8.07 | +103.1% | 12.38 | +32.4% |
| Net margin (%) | 27.5 | 15.2 | 21.7 |
Consolidated
- Filed with BSE
- 17 Aug 2020, 09:05 IST
- Board meeting
- 14 Aug 2020
- Period
- 01 Apr 2020 to 30 Jun 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 17 Aug 2020, 09:05 IST
- Board meeting
- 14 Aug 2020
- Period
- 01 Apr 2020 to 30 Jun 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE